Expression and clinical significance of SYNE3 in non-small cell lung cancer DOI
Yunxi Wu,

Dehe Chen,

Yu Luo

et al.

American Journal of Translational Research, Journal Year: 2024, Volume and Issue: 16(9), P. 4436 - 4449

Published: Jan. 1, 2024

To detect the expression of Spectrin Repeat Containing Nuclear Envelope Family Member 3 (SYNE3) and Cluster Differentiation 34 (CD34) in non-small cell lung cancer (NSCLC). It also aimed to explore relationship between SYNE3 NSCLC angiogenesis clinicopathologic features identify new biomarkers for NSCLC.

Language: Английский

Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC) DOI Open Access

Syeda A. Mina,

Mohamed Shanshal, Konstantinos Leventakos

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 353 - 353

Published: Jan. 22, 2025

Targeted therapies have changed the treatment landscape of non-small-cell lung cancer and led to improved patient survival across all stages cancer. Newer advances in common novel oncogenic drivers continue occur at vigorous speed, making it challenging stay up date with rapidly evolving field. In this article, we review emerging perspectives actionable targets We focus on development newer KRAS-directed therapies, particularly non-G12C mutations, pan-RAS inhibitors, RAS-GTP inhibitors. also describe current standard care for EGFR- ALK-altered NSCLC dive into treatments expected be clinic soon. A similar approach is taken toward MET, HER2, RET, ROS1, FGFR alterations as Finally, conclude body evidence targeting TROP-2 a target, potentially importance post-targeted therapy scenarios.

Language: Английский

Citations

2
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations DOI
William McCoull, Clare Thomson,

Erin Braybrooke

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Despite recent advances in the inhibition of EGFR (epidermal growth factor receptor), there remains a clinical need for new Exon20 insertion (Ex20Ins) inhibitors that spare WT. Herein, we report discovery and optimization two chemical series leading to ether 23 biaryl 36 as potent, selective, brain-penetrant Ex20Ins mutants. Building on our earlier alkyne 5 which allowed access CNS property space an inhibitor, utilized structure-based design move lower lipophilicity CLint compounds while maintaining WT selectivity margin. During optimization, aldehyde oxidase (AO) metabolism was identified human clearance risk, through SAR exploration, AO achieved. Potency margin were optimized across range mutants including potential acquired resistance T790M mutant efficacy demonstrated LXF2478 ASV model with vivo.

Language: Английский

Citations

0
Establishment and validation of a survival prediction model for stage IV non-small cell lung cancer: a real-world study DOI Creative Commons

Keao Zheng,

Junyan Zhang,

Xu Tingting

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 6, 2025

The aim of this study is to develop and validate a predictive model for predicting survival in individual advanced non-small cell lung cancer patients by integrating basic patient information clinical data. A total 462 with collected from Shanxi Cancer Hospital were randomly assigned (in 7:3 ratio) training cohort an internal validation cohort. Independent factors affecting patients' 3-year screened models created using single-factor followed multifactor Cox regression analysis. Evaluate the performance consistency index (C-index), calibration curves, receiver operating characteristic curves (ROC) decision curve analysis (DCA). who received chemotherapy alone those combined immunotherapy statistically paired propensity score matching between two groups, subgroup analyses performed among variables. better prognostic was nomogram chart visualizing drawn. Based on median risk cohort, all individuals categorized into high- low-risk high-risk group having worse OS both cohorts (P<0.05). results showed that versus NSCLC affected OS. developed predict cancer. demonstrated superior alone.

Language: Английский

Citations

0
Annual review of EGFR inhibitors in 2024 DOI

Chao Gao,

Wanning Wang,

Ying Liu

et al.

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 292, P. 117677 - 117677

Published: April 25, 2025

Language: Английский

Citations

0
Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway DOI

Xiangdan Cuan,

Yang Xing-ying,

Jinxian Wang

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 153, P. 107808 - 107808

Published: Sept. 7, 2024

Language: Английский

Citations

1
Expression and clinical significance of SYNE3 in non-small cell lung cancer DOI
Yunxi Wu,

Dehe Chen,

Yu Luo

et al.

American Journal of Translational Research, Journal Year: 2024, Volume and Issue: 16(9), P. 4436 - 4449

Published: Jan. 1, 2024

To detect the expression of Spectrin Repeat Containing Nuclear Envelope Family Member 3 (SYNE3) and Cluster Differentiation 34 (CD34) in non-small cell lung cancer (NSCLC). It also aimed to explore relationship between SYNE3 NSCLC angiogenesis clinicopathologic features identify new biomarkers for NSCLC.

Language: Английский

Citations

1